



Newborn Screening Quality Assurance Program

PROFICIENCY TESTING

Toxoplasma Quarterly Report

Volume 8, No. 2

May 2012

INTRODUCTION

This report is the quarterly summary of all data reported within the specified data-reporting period for Quarter 2, 2012. The attached tables provide the certification profiles for the distributed specimens, the verification of your reported data, the statistical analysis of the quantitative data, and the frequency distribution summaries for expected interpretations. We distribute this PT report to all participants, state laboratory directors, and program colleagues by request.

On April 9, 2012, a panel of five unknown dried-blood-spot (DBS) specimens prepared from human serum positive for exposure to *Toxoplasma gondii* was distributed to two laboratories in the United States and seven laboratories in other countries. This panel was prepared from serum samples positive for *Toxoplasma* IgG and IgM purchased from SeraCare (Medford, Massachusetts) and from human serum positive for exposure to *Toxoplasma gondii* from a CDC specimen bank. All serum samples were mixed with washed red blood cells and the final hematocrit was adjusted to 50%.

PARTICIPANTS' RESULTS

We processed data from seven participants. Laboratories were asked to report IgM screening results in Absorbance (OD) or other units. In the statistical summary analysis, we did not include data that were outside the 99% confidence interval.

Three laboratories reported using an enzyme immunoassay; two used a fluorometric enzyme immunoassay; and two used a multiplexed platform. The expected anti-*Toxoplasma* IgM values were based on CDC assayed values.

Overall statistics from the enzyme immunoassay methods are summarized in Tables 1a - 1c. The frequency distribution of participants' interpretations for screening results is shown in Table 2 and the frequency distribution of participants' interpretations for confirmatory results is shown in Table 3.

Expected interpretations (qualitative assessments) may differ by participant because of specific assessment practices. Overall, participants reported two false-negative interpretations and one false-positive interpretation. Laboratory results were evaluated on the basis of the final answers provided (screening only or confirmatory results). The mean cutoff for the enzyme immunoassay methods was 0.223, with a range from 0.100 to 0.306 OD; the mean cutoff for the multiplexed methods was 120 UA/mL (arbitrary units/mL serum); and the mean cutoff for the fluorescence immunoassay methods was 6 EIU (enzyme immunoassay units/mL serum).

Participants were asked to confirm specimens that screened above their cutoff for sorting test results that were *Toxoplasma*-antibody reactive from those that were *Toxoplasma*-antibody non-reactive. Three laboratories provided confirmatory results using an EIA for IgG or a multiplexed platform for IgG. Based on final interpretations, these three laboratories reported no misclassifications. ❖

The Newborn Screening Quality Assurance Program will ship next quarter's Anti-*Toxoplasma* antibodies PT specimens on July 9, 2012. ❖

CDC/APHL

Direct inquiries to:
Centers for Disease Control and Prevention (CDC)
4770 Buford Highway, NE, MS/F43
Atlanta, GA 30341-3724

This program is cosponsored by the Centers for Disease Control and Prevention (CDC) and the Association of Public Health Laboratories (APHL).

Phone: 770-488-7945
FAX: 770-488-4255
E-mail: JMei@cdc.gov

Editor: Joanne Mei
Production: Connie Singleton



NEWBORN SCREENING QUALITY ASSURANCE PROGRAM

ANTI-TOXOPLASMA Antibodies

QUARTER 2 – MAY 2012

OVERALL STATISTICS – IgM

Table 1a. Screening Results – Enzyme Immunoassay Methods

Specimen	N	Outliers*	Mean (OD)**	UL (95%)	LL (95%)
212T1	3	0	0.453	1.013	0.000
212T2	3	0	1.324	1.775	0.873
212T3	3	0	0.096	0.237	0.000
212T4	3	0	0.901	1.286	0.515
212T5	3	0	0.131	0.295	0.000

* Outliers are not included in N UL = upper limit LL = lower limit

Table 1b. Screening Results – Multiplexed Immunoassay Methods

Specimen	N	Outliers*	Mean (UA/mL)***	UL (95%)	LL (95%)
212T1	2	0	74.8	76.0	73.5
212T2	2	0	275.2	277.7	272.7
212T3	2	0	38.4	42.9	33.8
212T4	2	0	78.1	83.1	73.1
212T5	2	0	43.2	48.3	38.0

* Outliers are not included in N UL = upper limit LL = lower limit

Table 1c. Screening Results – Fluorescence Immunoassay Methods

Specimen	N	Outliers*	Mean (EIU)****	UL (95%)	LL (95%)
212T1	2	0	50.5	89.6	11.4
212T2	2	0	206.1	215.5	196.7
212T3	2	0	2.8	7.5	0.0
212T4	2	0	187.2	226.1	148.2
212T5	2	0	6.9	26.0	0.0

* Outliers are not included in N UL = upper limit LL = lower limit

** OD = Absorbance units

*** UA/mL = Arbitrary units/mL serum

**** EIU = Enzyme immunoassay units/mL serum

Table 2. Frequency Distribution of Participants' Interpretations*
SCREENING RESULTS

Specimen	<i>Toxoplasma</i> antibody non-reactive	<i>Toxoplasma</i> antibody reactive
212T1	2	5
212T2	0	7
212T3	7	0
212T4	2	5
212T5	6	1

*All Methods

Table 3. Frequency Distribution of Participants' Interpretations*
CONFIRMATORY RESULTS

Specimen	<i>Toxoplasma</i> antibody non-reactive	<i>Toxoplasma</i> antibody reactive
212T1	0	3
212T2	0	3
212T3	3	0
212T4	0	3
212T5	3	0

*All methods

This *NEWBORN SCREENING QUALITY ASSURANCE PROGRAM* report is an internal publication distributed to program participants and selected program colleagues. The laboratory quality assurance program is a project cosponsored by the **Centers for Disease Control and Prevention (CDC)** and the **Association of Public Health Laboratories**.

CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC)
ATLANTA, GA 30341

Director

Thomas R. Frieden, M.D., M.P.H.

Director

National Center for Environmental Health

Christopher J. Portier, Ph.D.

Director

Division of Laboratory Sciences

James L. Pirkle, M.D., Ph.D.

Chief

Newborn Screening and Molecular Biology Branch

Carla Cuthbert, Ph.D.



Contributors: Barbara W. Adam
Carol Bell
Dana Chafin
Paul Dantonio
Sharon Flores
Victor R. De Jesus, Ph.D.
Marie C. Earley, Ph.D.
Tamara Ganka
Elizabeth M. Hall
Christopher Haynes, Ph.D.
Kevin Lanza
Francis Lee, Ph.D.
Lixia Li, Ph.D.
Timothy Lim, Ph.D.
Joanne Mei, Ph.D.
Nancy Meredith
Tracey Myers
Jennifer Taylor
Robert Vogt, Ph.D.
Golriz Yazdanpanah
Hui Zhou, Ph.D.
Sherri Zobel

Production: Sarah Brown
Felicia Manning
Teresa Moore
Connie Singleton



ASSOCIATION OF PUBLIC HEALTH LABORATORIES
SILVER SPRING, MD 20910

President

Victor Waddell, Ph.D.

Chairman, Newborn Screening and Genetics in Public Health Committee

Susan M. Tanksley, Ph.D.

Chairman, Newborn Screening Quality Assurance Quality Control Subcommittee

Patrick Hopkin, B.S.

INQUIRIES TO:

Joanne Mei, Editor • Centers for Disease Control and Prevention (CDC)
Newborn Screening Quality Assurance Program • Mailstop F-43
4770 Buford Highway, N.E. • Atlanta, GA 30341-3724
Phone (770) 488-4582 • FAX (770) 488-4255 • E-mail: JMei@cdc.gov